Therapeutic HPV vaccine may improve outcomes in advanced cervical cancer

0
1


(American Association for the Advancement of Science) Combining a therapeutic vaccine for human papilloma virus (HPV) with two standard chemotherapy drugs may extend survival in patients with advanced, recurrent cervical cancer, according to a phase 1/2 trial involving 77 patients.

Related Links:

Publication date: Available online 30 January 2020Source: The LancetAuthor(s): Karen Canfell, Jane J Kim, Marc Brisson, Adam Keane, Kate T Simms, Michael Caruana, Emily A Burger, Dave Martin, Diep T N Nguyen, Élodie Bénard, Stephen Sy, Catherine Regan, Mélanie Drolet, Guillaume Gingras, Jean-Francois Laprise, Julie Torode, Megan A Smith, Elena Fidarova, Dario Trapani, Freddie BraySummaryBackgroundWHO is developing a global strategy towards eliminating cervical cancer as a public health problem, which proposes an elimination threshold of four cases per 100 000 women and includes 2030 triple-interventi…

Source: The LancetCategory: General Medicine Source Type: research

CONCLUSION: Recent research developments have led to an entirely new class of drugs using antibodies against the PD-L1/PD-1 thus promoting the body’s immune system to fight the cancer. The expression and roles of the PD-L1/ PD-1 axis in the progression of cervical cancer provide great potential for using PD-L1/PD-1 antibodies as a targeted cancer therapy.
PMID: 32003657 [PubMed – as supplied by publisher]

Source: Current Medicinal ChemistryCategory: Chemistry Authors: Tags: Curr Med Chem Source Type: research

BOSTON (CBS) – January is cervical cancer awareness month and Kate Weissman of Charlestown is hoping her story will inspire women to get potentially life-saving screening tests.
Four years ago, she heard the words that everyone dreads – “You have cancer.”
“It was devastating,” she recalls thinking of that moment alone in her apartment. “I just said to myself, I’m 30 and I’m going to die.”
Weissman endured months of grueling treatment. Doctors initially thought they got it all, but the cancer turned up in her lymph nodes. So she had to go back for more treatment, a…

Authors: Sun W, Shen NM, Fu SL
Abstract
Cervical cancer (CC) develops, after human papillomavirus (HPV), an infection transmitted through sexual contact. Worldwide estimates are around>500,000 CC diagnoses and>300,000 related deaths annually, and CC remains the second most devastating type of cancers in women after breast cancer. Although the vaccine against HPV has reduced the incidence of infection and the treatment efficacy of the early-stage diagnoses has improved, many challenges remain in terms of treatment efficacy, during the late-stage and prevention of chemotherapy resistance development. Thus, new …

AbstractHigh-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially control tumor progression, highlighting the necessity to investigate different treatment strategies. Using the genital orthotopic HPV16 TC-1 model, herein we sequentially investigated in progressively more stringent settings the effects of systemic administration of carboplatin/paclitaxel (C  + P) chemotherapy combined with HPV16-E7 synthetic long peptide (E7LP) vaccination, followed by intravagina…

CONCLUSIONS: These potential biomarkers may offer insights to further personalize therapeutic decision-making to improve survival in HPV- cervical cancer patients.
PMID: 30581036 [PubMed – as supplied by publisher]

Source: Gynecologic OncologyCategory: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research

Human papillomavirus (HPV) has been associated with the cause of several cancer types, including cervical, anal, and head and neck cancers. There has been great success in preventing HPV infections with the development of prophylactic HPV vaccines, Gardasil and Cervarix. However, these vaccines have only been shown to prevent HPV infection and not treat those already infected with HPV. These vaccines elicit antibody responses to late HPV genes, and thus would not be effective in treating established tumors. To date, no therapeutic HPV vaccine has been approved by the FDA, and there is an unmet need for therapeutic vaccines…

The World Health Organization (WHO) estimates more 270000 deaths annually by cervical cancer. Present vaccines are prophylactic in nature which cannot treat huge bulk of cervical cancer patients worldwide. Available therapies like radiotherapy, chemotherapy or surgery are not effective in high grade lesion and hence, there is an unmet medical need for an effective form of therapy. T cells play a significant role in cervical cancer pathogenesis as Human Papilloma Virus (HPV) uses multiple mechanisms that dodge host T cell immune-surveillance aiding in persistence of infection and establishment of cancer.

Source: Current Problems in CancerCategory: Cancer & Oncology Authors: Source Type: research

The World Health Organization estimates more than 270,000 deaths annually by cervical cancer. Present vaccines are prophylactic in nature which cannot treat huge bulk of cervical cancer patients worldwide. Available therapies like radiotherapy, chemotherapy, or surgery are not effective in high-grade lesion, and hence, there is an unmet medical need for an effective form of therapy. T cells play a significant role in cervical cancer pathogenesis as human papilloma virus uses multiple mechanisms that dodge host T-cell immune-surveillance aiding in persistence of infection and establishment of cancer.

Source: Current Problems in CancerCategory: Cancer & Oncology Authors: Source Type: research

The World Health Organization (WHO) estimates more 270000 deaths annually by cervical cancer. Present vaccines are prophylactic in nature which cannot treat huge bulk of cervical cancer patients worldwide. Available therapies like radiotherapy, chemotherapy or surgery are not effective in high grade lesion and hence, there is an unmet medical need for an effective form of therapy. T cells play a significant role in cervical cancer pathogenesis as Human Papilloma Virus (HPV) uses multiple mechanisms that dodge host T cell immune-surveillance aiding in persistence of infection and establishment of cancer.

Source: Current Problems in CancerCategory: Cancer & Oncology Authors: Source Type: research



Source link